Equities

Axsome Therapeutics Inc

Axsome Therapeutics Inc

Actions
  • Price (USD)79.80
  • Today's Change0.63 / 0.80%
  • Shares traded487.70k
  • 1 Year change+29.74%
  • Beta1.1208
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

  • Revenue in USD (TTM)270.60m
  • Net income in USD-239.24m
  • Incorporated2012
  • Employees545.00
  • Location
    Axsome Therapeutics IncOne World Trade Center, 22Nd FloorNEW YORK 10007United StatesUSA
  • Phone+1 (212) 332-3241
  • Fax+1 (212) 320-0245
  • Websitehttps://www.axsome.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hims & Hers Health Inc872.00m-23.55m3.37bn1.05k--9.77--3.87-0.1131-0.11314.171.612.167.13195.17833,652.00-5.83---7.02--81.99---2.70--2.74--0.00--65.49--64.15------
Simply Good Foods Co1.25bn133.28m3.38bn271.0025.672.1021.942.711.321.3212.3916.100.59436.418.494,614,288.006.333.666.583.8336.5938.9010.666.803.467.780.14480.006.3323.5623.0313.6547.09--
Alvotech SA93.38m-551.73m3.38bn999.00------36.23-2.40-2.400.4109-3.490.1052.201.3993,475.48-62.04---81.72---72.26---590.83--0.4614-1.297.52--9.84---7.43------
Crinetics Pharmaceuticals Inc4.01m-214.53m3.46bn290.00--5.62--862.80-3.70-3.700.06917.910.0081--0.704813,837.93-42.39-42.53-45.71-45.36-----5,216.32-5,446.39----0.00---15.2810.57-30.88--34.65--
Amicus Therapeutics, Inc.399.36m-151.58m3.50bn517.00--21.74--8.77-0.5148-0.51481.350.54560.53180.89395.19772,448.80-20.18-30.65-25.36-36.5590.6588.94-37.96-86.102.52-1.760.7077--21.3034.3535.92--3.36--
Arrowhead Pharmaceuticals Inc181.74m-296.81m3.56bn525.00--19.23--19.57-2.77-2.771.691.490.2395----346,171.40-39.91-20.02-46.61-24.65-----166.63-61.79---55.190.00---1.0371.68-16.59--162.38--
Fortrea Holdings Inc3.11bn-3.40m3.58bn18.00k--2.0538.531.15-0.0379-0.037935.0319.58------172,722.20--------16.74---0.1094----1.270.478--0.4167---101.76------
Immunitybio Inc622.00k-583.20m3.68bn628.00------5,916.04-1.13-1.130.0012-0.8750.0014--0.246990.45-134.71-112.76-377.77-316.07-----93,866.88-37,700.74---2.083.32--159.1767.62-40.00--18.48--
SpringWorks Therapeutics Inc5.45m-325.10m3.70bn305.00--5.88--678.67-5.14-5.140.08628.520.008----17,859.02-47.95-36.97-53.00-39.4992.25---5,968.50-2,176.466.37--0.00-------17.19--90.68--
Arcellx Inc110.32m-70.69m3.72bn130.00--7.59--33.72-1.49-1.492.309.280.1937----848,607.70-12.41-38.82-14.67-45.41-----64.08-339.38----0.0749------62.53--113.86--
Axsome Therapeutics Inc270.60m-239.24m3.75bn545.00--19.63--13.86-5.20-5.205.964.030.58852.684.08496,513.80-52.02-64.55-69.92-82.2390.37---88.41-227.053.52-35.930.4825--440.80---27.84--77.86--
Ultragenyx Pharmaceutical Inc434.25m-606.64m3.85bn1.28k--13.99--8.88-8.33-8.335.913.350.2861.497.63340,320.50-39.96-33.35-48.63-38.3089.5993.13-139.70-154.712.49--0.00--19.5253.1814.25--62.91--
Apogee Therapeutics Inc0.00-83.99m3.91bn91.00--8.67-----1.74-1.740.007.86------0.00--------------------0.00-------111.10------
Iovance Biotherapeutics Inc1.19m-444.04m3.94bn557.00--6.18--3,312.22-1.89-1.890.00512.280.0017----2,134.65-61.49-51.47-71.47-57.56-804.54---37,345.42-137,873.802.70--0.0017-------12.16--79.44--
Insmed Inc305.21m-749.57m4.06bn912.00------13.29-5.35-5.352.17-2.240.20440.85628.61334,657.90-50.20-40.96-58.32-46.8878.5277.99-245.59-212.923.75-17.211.39--24.3998.78-55.66---2.15--
Data as of Mar 28 2024. Currency figures normalised to Axsome Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

42.51%Per cent of shares held by top holders
HolderShares% Held
RTW Investments LPas of 31 Dec 20234.49m9.48%
The Vanguard Group, Inc.as of 31 Dec 20233.60m7.59%
BlackRock Fund Advisorsas of 31 Dec 20232.80m5.92%
Fairmount Funds Management LLCas of 31 Dec 20232.36m4.98%
BVF Partners LPas of 31 Dec 20231.98m4.18%
Perceptive Advisors LLCas of 31 Dec 20231.04m2.19%
Deep Track Capital LPas of 31 Dec 20231.00m2.11%
RA Capital Management LPas of 31 Dec 20231.00m2.11%
Citadel Advisors LLCas of 31 Dec 2023947.67k2.00%
SSgA Funds Management, Inc.as of 31 Dec 2023924.19k1.95%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.